Nicotinamide
specialtyAlso known as: Nicotinamide (high-dose oral), Vitamin B3 (oral oncology dose)
About
Nicotinamide at chemoprevention doses replenishes cellular NAD+ depleted by UV-induced PARP activation, enhancing cellular energy for DNA repair. The landmark ONTRAC trial (386 patients, NEJM 2015) found nicotinamide 500 mg twice daily reduced new nonmelanoma skin cancers by 23% and actinic keratoses by 11% in high-risk individuals.
How It Works
Amide form of vitamin B3 (distinct from niacinamide in dosing context); replenishes cellular NAD+ depleted by UV-induced PARP activation; enhances cellular energy for DNA repair; supports immune surveillance of skin cancer precursors; strengthens skin barrier ceramide synthesis.
Evidence For Conditions
| Condition | Grade | Studies | Participants | |
|---|---|---|---|---|
| UV Protection (Internal Photoprotection) | A | 5 | 686 | View → |
Side Effects
- Generally well-tolerated (no flushing)
- Mild gastrointestinal discomfort at high doses
- Rare hepatotoxicity at very high doses
Drug & Supplement Interactions
- Anticonvulsants (carbamazepine — may increase levels)
- Isoniazid (competes for NAD+ pathways)
- Hepatotoxic drugs (potential additive liver effect at high doses)
Always inform your healthcare provider about all supplements you take.
Related Ingredients
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.